Turning Point 2022 - Dana-Farber Cancer Institute | Boston, MA

Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Turning Point 2022

A selection of articles from the 2022 issue of Turning Point.

To see the entire issue of Turning Point, please download the PDF version. If you'd like to receive a print version of Turning Point in the mail, please complete this form.

Seeking Signs of Synergy

How science, collaboration, and persistence fueled a promising new drug combination for ovarian cancer.

Piecing Together the Next Chapter of PARP Inhibitors

Dana-Farber researchers devise powerful new drug pairings to improve the effectiveness of ovarian cancer therapies.

Guiding Patients Through Treatment

Exploring the nursing team's vital and complex role in oncology care.

Putting the Spotlight on Rare Cancers

Through collaboration, fortitude, and ingenuity, Dana-Farber researchers are advancing potential new treatments for a variety of rare cancer subtypes.

Turning Point is published for supporters of the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute.

Comments, suggestions, and requests to be added to or deleted from the mailing list may be sent to:

Turning Point
Dana-Farber Cancer Institute
Department of Communications
450 Brookline Ave.
Boston, MA 02215
Phone: 617-632-4090
Email: TurningPoint@dfci.harvard.edu

Posted on December 21, 2022

Email

Media Contacts
If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.
The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.
Request a Publication
Receive by mail the current issue of a Dana-Farber publication by completing this request form.